"3D is an extremely effective communications firm, and an excellent partner. They do their homework, come with good ideas in both content and delivery on complex issues, and help us articulate our messages in a meaningful way."
"3D guided us in getting our information "just right" for important audiences, from the FDA to the investment community."
"The 3D presentation on preparation for advisory committees was very well received and enjoyed by the Indiana RAPS Chapter. Our feedback forms indicated that it exceeded the expectations of the attendees."
Gretchen Miller Bowker, RAC, FRAPS
Chief Operating Officer
"The participants found the meeting engaging, as well as educational and entertaining. The use of videos and personal anecdotes was very effective. The formal feedback we had from the attendees was uniformly positive, even effusive -- with several commenting that it was one of our best meetings ever."
San Francisco Bay Area RAPS Chapter Program Board
"The presentation included excellent examples of a well-prepared company for a successful ad com meeting. If you have never presented at an FDA Advisory Committee meeting, 3D Communications can help prepare you for one of your company's most important steps toward new product introduction."
Joe Curtis, RAC
RAPS Boston Chapter
"The presentation regarding FDA panel meeting was energetic and informative. The overview of the planning for a panel meeting and examples of execution were insightful."
Memphis Regulatory Consulting, LLC
"I very much enjoyed your engaging presentation, the fascinating (and sometimes painful) video footage of FDA Panel meetings, and the interactive Q&A section at the end. The attendee comments included: "excellent presenter" and "well worth the time."
VP, Regulatory Affairs
"Jim was an engaging and entertaining speaker. He portrayed a clear command of advisory committees and the business realities involved. One of the participants exclaimed afterwards, "I would hire him if we ended up in front of an advisory panel."
Daniel Biank, JD, PE, RAC
"3D's roundtable was very informative and insightful on how to take the most advantageous approach to preparing for advisory committee meetings. I would certainly keep 3D Communications on my short list of must have vendors for this very important step in the process of approval. Thank you for your time!"
Marian Saxon Rhodes, PhD, RAC
"3D's presentation to RAPS was both informative and entertaining. It was the perfect combination of regulatory insight and how to get to know your advisory committee, how to help your team prepare, and how to avoid the most common mistakes companies make. It's important information for anyone preparing for an FDA advisory committee meeting!"
Compliance Alliance, LLC
"The combination of 3D's personal experiences in advisory committee meetings and their in-depth knowledge of excellent presentation techniques provided us with an informative and educational evening."
Jamie Robinson, RAC
Associate Program Director, Pharma Technical Regulatory
"3D's expertise and guidance was critical in helping us prepare for ODAC."
Edda Gomez-Panzani, MD
Vice President, Clinical Development, Endocrinology
"You really whipped us into shape. We all learned a lot about how best to present and defend our position. These important learnings will find applicability beyond yesterday's event."
VP of Global Regulatory Affairs
"Cindy was kind enough to teach a unit of my graduate class. She was informative, dynamic, and engaging. Her course materials were outstanding. She shared her book with the class. The students ranked her presentation 5 out of 5 on the feedback form. Thank you, Cindy!"
Andrea Chamblee, RAC
Supervisory Regulatory Counsel
Food and Drug Administration
"3D's communications coaching was immediately impactful & a tremendous value-add. Our team's communications are more crisp, confident and persuasive - essential qualities for successful advocacy in policy and politics."
Mehlman Castagnetti Rosen Bingel & Thomas
3D Communications was what made the difference. They know how to tell a credible story that resonates with the FDA Advisory Committee.
Lynn Webster, MD
VP Scientific Affairs
PRA Life Sciences